Intermittent Claudication Clinical Trial
Official title:
The PaWS (Pedometer and Walking Study): Comparing Education Alone and Education With Pedometer/Exercise Log Use in Self-monitored Walking in Peripheral Arterial Disease (PAD)
The literature has shown that supervised exercise programs for patients with PAD and who report intermittent claudication (IC) have improved health outcomes, but this is not locally available. Introducing the use of a pedometer may act as a method to encourage patients to continue on their independent exercise regimen. There is very little literature which has examined the effectiveness using pedometers as a measure of compliance within this population.
It has been established that exercise therapy has a central role in the management of
peripheral arterial disease. Such treatment should be comprised of intermittent walking of
sufficient distance to induce significant discomfort, and be carried out over a period of at
least several months. Supervised exercise training utilizing intermittent treadmill walking
is a well-validated treatment for claudication. Most prospective randomized single site
studies have reported significant improvement in walking distance following supervised
exercise training but not with non-supervised regimens.
Furthermore, this has been acknowledged in both the current AHA/ACC 'Guidelines for the
management of patients with peripheral arterial disease', which recommends supervised
exercise training as an initial treatment modality with a Class 1A level of evidence
(highest), as well as in the TransAtlantic Intersocietal Consensus, which provides an 'A'
categorical recommendation. In spite of these peer-reviewed, published recommendations,
supervised exercise training remains little used, expensive, not reimbursed by Ontario
Health Insurance Plan, and therefore is rarely available to patients with claudication in
Ontario.
The purpose of this multicentre study is to examine whether the use of a pedometer enhances
patient compliance with walking as compared to usual care.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400395 -
Clinical Trial for GNX80 in Intermittent Claudication
|
Phase 4 | |
Active, not recruiting |
NCT02341716 -
Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication
|
N/A | |
Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Recruiting |
NCT00538408 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients
|
N/A | |
Completed |
NCT00618670 -
Home-based vs. Supervised Exercise for People With Claudication
|
N/A | |
Completed |
NCT00388128 -
Caffeine and Intermittent Claudication
|
Phase 3 | |
Recruiting |
NCT00146666 -
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
|
Phase 2 | |
Completed |
NCT00134277 -
Trial Comparing Different Medical Devices for Infragenual Dilatation
|
N/A | |
Completed |
NCT01256775 -
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299956 -
Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark
|
N/A | |
Not yet recruiting |
NCT05335161 -
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
|
Phase 1 | |
Completed |
NCT04390282 -
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication
|
N/A | |
Completed |
NCT03271710 -
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
|
N/A | |
Completed |
NCT02380794 -
Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
|
Phase 2 | |
Active, not recruiting |
NCT02276937 -
Randomized Phase IIb Trial of DVC1-0101
|
Phase 2 | |
Completed |
NCT02097082 -
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00071266 -
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
|
Phase 3 |